Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T24211
|
||||
Former ID |
TTDI02289
|
||||
Target Name |
C1 esterase inhibitor
|
||||
Gene Name |
SERPING1
|
||||
Synonyms |
C1 Inh; C1Inh; C1inhibiting factor; Plasma protease C1 inhibitor; Serpin G1; SERPING1
|
||||
Target Type |
Successful
|
||||
Disease | Hereditary angioedema [ICD9: 277.6; ICD10: D84.1] | ||||
Function |
Activation of the C1 complex is under control of the C1- inhibitor. It forms a proteolytically inactive stoichiometric complex with the C1r or C1s proteases. May play a potentially crucial role in regulating important physiological pathways including complement activation, blood coagulation, fibrinolysis and the generation of kinins. Very efficient inhibitor of FXIIa. Inhibits chymotrypsin and kallikrein. {ECO:0000269|PubMed:8495195}.
|
||||
BioChemical Class |
Serpin family
|
||||
UniProt ID | |||||
Sequence |
MASRLTLLTLLLLLLAGDRASSNPNATSSSSQDPESLQDRGEGKVATTVISKMLFVEPIL
EVSSLPTTNSTTNSATKITANTTDEPTTQPTTEPTTQPTIQPTQPTTQLPTDSPTQPTTG SFCPGPVTLCSDLESHSTEAVLGDALVDFSLKLYHAFSAMKKVETNMAFSPFSIASLLTQ VLLGAGENTKTNLESILSYPKDFTCVHQALKGFTTKGVTSVSQIFHSPDLAIRDTFVNAS RTLYSSSPRVLSNNSDANLELINTWVAKNTNNKISRLLDSLPSDTRLVLLNAIYLSAKWK TTFDPKKTRMEPFHFKNSVIKVPMMNSKKYPVAHFIDQTLKAKVGQLQLSHNLSLVILVP QNLKHRLEDMEQALSPSVFKAIMEKLEMSKFQPTLLTLPRIKVTTSQDMLSIMEKLEFFD FSYDLNLCGLTEDPDLQVSAMQHQTVLELTETGVEAAAASAISVARTLLVFEVQQPFLFV LWDQQHKFPVFMGRVYDPRA |
||||
Drugs and Mode of Action | |||||
Drug(s) | Cinryze | Drug Info | Approved | Hereditary angioedema | [1] |
Rhucin | Drug Info | Approved | Hereditary angioedema | [2], [3] | |
Modulator | Cinryze | Drug Info | [4] | ||
Rhucin | Drug Info | [2], [3] | |||
References | |||||
REF 1 | Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87. | ||||
REF 2 | Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. | ||||
REF 3 | Recombinant human c1 inhibitor (conestat alfa): in the treatment of angioedema attacks in hereditary angioedema. BioDrugs. 2012 Oct 1;26(5):315-23. | ||||
REF 4 | 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.